Brought to you by 
Series C brings in $80mm for Relypsa
16 Aug 2012
Executive Summary
Cardiovascular and renal therapeutics developer Relypsa Inc. has raised $80mm through its Series C venture round. There were 13 backers, including existing shareholders OrbiMed Advisors, 5AM Ventures, New Leaf Venture Partners, Sprout Group, Delphi Ventures, and Mediphase Venture Partners, and new investor Sibling Capital. Relypsa will use the funds for continued development, NDA submission, and eventual marketing of patiromer (RLY5016), a Phase III-ready non-absorbed oral potassium binder.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C brings in $80mm for Relypsa
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice